Soterix Medical

15 articles with Soterix Medical

• Soterix Medical Announces award of Fast Track NIH grant to develop a Parcel-Guided software to improve efficacy of rTMS treatment for Depression

  10/13/2022

  Soterix Medical Inc. (SMI), a global leader in non-invasive neuromodulation and synergistic brain monitoring technologies, announced today that it has been awarded a Fast Track grant from the National Institute of Mental Health (NIMH).

• Wise Therapeutics and Soterix Medical Jointly Announce Positive Results of Study Combining Gamified Digital Therapeutics with Neurostimulation Device

  6/30/2021

    Wise Therapeutics  (Wise), a developer of game-based digital therapeutics including Personal Zen , and Soterix Medical jointly announced the results of their collaborative study, published in Frontiers in Neuroergonomics.

• Soterix Medical Announces Expanded Clinical Trials for Alzheimer's disease and Mild Cognitive Impairment

  12/24/2020

    Soterix Medical Inc. , the global leader in non-invasive stimulation and synergistic brain imaging technologies, is pleased to report expanded clinical trials of its proprietary neuromodulation technologies for Alzheimer's disease and Mild Cognitive Impairment. Adults over age 65 represent the fastest growing population in the US. Dec

• FDA Grants Soterix Medical IDE Approval for Home-based tDCS-LTE Trial for Depression

  7/7/2020

  Soterix Medical Inc. announces it has received FDA Investigational Device Exception (IDE) to launch a trial of transcranial Direct Current Stimulation-Limited Total Energy (tDCS-LTE) neuromodulation at-home for patients with Major Depressive Disorder (MDD)

• Soterix Medical Announces launch of electro-detox Treatment for Opioid Withdrawal

  5/15/2019

  Soterix Medical Inc. announced the launch of its U.S. Food and Drug Administration 510k cleared electro-detox™ treatment to reduce opiate and opioid withdrawal symptoms.

• Soterix Medical Expands South East Asia Presence With Clinical Approval in Singapore for Depression and Fibromyalgia Treatment

  11/29/2017

  This approval allows Soterix Medical to immediately market its products based on its proprietary transcranial Direct Current Stimulation (tDCS) technology in Singapore.

• FDA Clears Soterix Medical's IontoDC System

  5/22/2017

• Soterix Medical Receives ANVISA Medical Device Approval In Brazil For Neuromodulation Products Including Painx And Depression-LTE Treatment

  4/13/2017

• Soterix Medical Launches PainX tDCS Treatment In Canada With Health Canada Approval

  9/28/2016

• Soterix Medical Awarded $2.5 Million NIH Grant To Run Phase-II Efficacy Trial To Treat Aphasia After Stroke With HD-Tdcs

  6/15/2016

• Soterix Medical Launches PainX tDCS Treatment in EU with CE Approval

  1/15/2016

• Soterix Medical Receives CE Mark Approval for 1x1 tDCS Depression Therapy

  12/30/2015

• Soterix Medical Awarded Patent For Limited Energy Neuromodulation

  11/21/2014

• Electrical Geodesics, Inc. Distribution Agreement With Soterix Medical

  6/12/2014

• Soterix Medical Announces Phase 3 Clinical Trial for Depression Comparing tDCS-LTE Against Antidepressant Drug (Escitalopram)

  10/29/2013